These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 17496428)

  • 1. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer.
    Shen J; Zhu Z
    Curr Opin Mol Ther; 2008 Jun; 10(3):273-84. PubMed ID: 18535935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabodies: molecular engineering and therapeutic applications.
    Wu C
    Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dual-specificity therapeutic antibodies].
    Winckler T
    Pharm Unserer Zeit; 2009; 38(5):395-6. PubMed ID: 19711313
    [No Abstract]   [Full Text] [Related]  

  • 10. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies as novel bioconjugates.
    Cao Y; Suresh MR
    Bioconjug Chem; 1998; 9(6):635-44. PubMed ID: 9815155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bivalent monoclonal IgY antibody formats by conversion of recombinant antibody fragments.
    Greunke K; Spillner E; Braren I; Seismann H; Kainz S; Hahn U; Grunwald T; Bredehorst R
    J Biotechnol; 2006 Jul; 124(2):446-56. PubMed ID: 16490273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Therapeutic monoclonal antibodies: a little history, a lot of engineering, and... some clinical successes].
    Siberil S; Dutertre CA; Boix C; Teillaud JL
    Transfus Clin Biol; 2005 Jun; 12(2):114-22. PubMed ID: 15907389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of bispecific and trispecific F(ab)2 and F(ab)3 antibody derivatives.
    French RR
    Methods Mol Biol; 1998; 80():121-34. PubMed ID: 9664369
    [No Abstract]   [Full Text] [Related]  

  • 15. Bispecific antibody derivatives based on full-length IgG formats.
    Grote M; Haas AK; Klein C; Schaefer W; Brinkmann U
    Methods Mol Biol; 2012; 901():247-63. PubMed ID: 22723106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status and prospects of antibody engineering for therapeutic use: focus on glycoengineering technology.
    Niwa R; Satoh M
    J Pharm Sci; 2015 Mar; 104(3):930-41. PubMed ID: 25583555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The assembly of single domain antibodies into bispecific decavalent molecules.
    Stone E; Hirama T; Tanha J; Tong-Sevinc H; Li S; MacKenzie CR; Zhang J
    J Immunol Methods; 2007 Jan; 318(1-2):88-94. PubMed ID: 17141798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin.
    Wu C; Ying H; Grinnell C; Bryant S; Miller R; Clabbers A; Bose S; McCarthy D; Zhu RR; Santora L; Davis-Taber R; Kunes Y; Fung E; Schwartz A; Sakorafas P; Gu J; Tarcsa E; Murtaza A; Ghayur T
    Nat Biotechnol; 2007 Nov; 25(11):1290-7. PubMed ID: 17934452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
    Acheampong DO
    Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tethered-variable CL bispecific IgG: an antibody platform for rapid bispecific antibody screening.
    Kim HS; Dunshee DR; Yee A; Tong RK; Kim I; Farahi F; Hongo JA; Ernst JA; Sonoda J; Spiess C
    Protein Eng Des Sel; 2017 Sep; 30(9):627-637. PubMed ID: 28985411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.